Saturday, May 31, 2014

FDA warns against recalled anti-depression drugs

May 27, 2014 8:06pm
 
Philippine health authorities on Tuesday advised the public against buying three batches of anti-depression drugs that had been recalled by their manufacturer.
 
The Food and Drug Administration said GlaxoSmithKline USA recalled batches of its Paroxetine 20mg tablet (Seroxat) that were made in Romania.
 
"A Warning Letter was issued by the US FDA to GlaxoSmithKline (GSK), USA because the active Pharmaceutical Ingredients (API) manufacturer, SmithKline Beecham (Cork) Ltd. at Currabinny Carriagaline Cork, Ireland had critical deviations which caused the Paroxetine API to be adulterated," FDA head Kenneth Hartigan-Go said in FDA Advisory 2014-038.
 

While the advisory was dated May 12, it was posted on the FDA website only on Tuesday.
 
Covered by the voluntary recall are batches 601, 602M, and 603.
 
Hartigan-Go said proxetine is used for treatment of depression, obsessive-compulsive disorder and panic disorder with or without agoraphobia or the fear of public places.
 
The FDA advised consumers to buy their medicines from legitimate pharmacies and drug outlets and ask for official receipts.
 
"If you happen to buy batches of Seroxat that are subject of product recall, the consumer may report to FDA via report@fda.gov.ph or to GalxoSmithKline Philippines Inc at tel. nos.: +6328648516 and +6328920762 ext. 8643 or mobile nos.: +639178882315 and+639178594598," it said.
 
Suspected adverse reactions should be reported immediately to FDA by visiting www.fda.gov.ph. Joel Locsin/NB, GMA News

FDA: Not all Eli Lilly products covered by recall order

May 30, 2014 5:29pm
The Food and Drug Administration on Friday said certain products from pharmaceutical firm Eli Lilly may still be sold, citing a stay order from the office of Health Secretary Enrique Ona.

In Advisory 2014-043 dated May 30, the FDA said the following products, which have valid product registration, are allowed in the Philippine market:
  • Gemzar 200mg Powder for IV Injection, DR-XY40364
  • Humulin 70/30 Vial, DR-XY14545
  • Humulin N Vial, DR-XY6181
  • Humulin R Vial, DR-XY6180
  • Humulin 70/30 Cartridge, DR-XY23452
  • Humulin N Cartridge, DR-XY23454
  • Zyprexa 5mg Tablet, DR-XY22855
  • Zyprexa 10mg Tablet, DR-XY22856
  • Alimta 100mg Lyophilized Powder for Intravenous Infusion, DR-XY35204
  • Alimta 500mg Lyophilized Powder for I.V. Infusion, DR-XY31536
  • Gemzar 1g Powder for Injection, DR-XY42100
  • Cymbalta 60mg Capsule, DR-XY41867
  • Zyprexa Zydis 5mg Tablet, DR-XY37273
  • Forteo 250mcg/mL Solution for Injection, DR-XY29234
  • Byetta 250mcg/mL Solution for Injection (1.2mL) SC, DR-XY33256
  • Byetta 250mcg/mL Solution for Injection (2.4mL) SC, DR-XY33264
  • Effient 5mg Film-Coated Tablet, DR-XY37670
  • Effient 10mg Film-Coated Tablet, DR-XY37671
  • Cymbalta 30mg Capsule, DR-XY31173
  • Zyprexa Zydis 10mg Orodispersible Tablet, DR-XY37455

Earlier this month, the FDA fined the pharmaceutical firm P16 million for importing and distributing unregistered products.

FDA also ordered the recall of 15 Eli Lilly Philippines products after finding they were either unregistered or had falsified product registrations.

Covered by the recall order were:

  • Cialis 20 mg Tablet
  • Cymbalta 30mg Capsule
  • Humalog 100 units per mL Solution for Injection
  • Humalog Kwikpen 100u/mL Solution for Injection
  • Humalog Mix 25 Kwikpen 100iu per mL Solution For Injection
  • Humalog Mix 25
  • Humalog Mix 50 Kwikpen
  • Stratterra 10mg Capsule
  • Stratterra 18mg Capsule
  • Stratterra 25mg Capsule
  • Straterra 40 mg Capsule
  • Strattera 60mg Capsule
  • Prozac 20mg Capsule
  • Zyprexa Zydis 10mg Orodispersible tablet
  • Zyprexa Intramascular 20mg Powder for Injection

Dr. Kenneth Hartigan-Go, FDA director,  said at the time that only the following Eli Lilly products have a certificate of product registration:

  • Alimta 100mg Lyophilized Powder for Intravenous Infusion, FDA registration number DR-XY35204
  • Alimta 500mg Lyophilized Powder for I.V. Infusion, DR-XY31536
  • Gemzar 1g Powder for Injection, DR-XY42100
  • Cymbalta 60mg Capsule, DR-XY41867
  • Zyprexa Zydis 5mg Tablet, DR-XY37273
  • Forteo 250mcg/mL Solution for Injection, DR-XY29234
  • Byetta 250mcg/mL Solution for Injection (1.2mL) SC, DR-XY33256
  • Byetta 250mcg/mL Solution for Injection (2.4mL) SC, DR-XY33264
  • Effient 5mg Film-Coated Tablet, DR-XY37670
  • Effient 10mg Film-Coated Tablet, DR-XY37671

The FDA advised the public to email for inquiries. Those who want to report unregistered health products and adverse reactions after using any health product may email the FDA. Joel Locsin/JDS, GMA News

Friday, May 30, 2014

Washington Post: Five Myths About the Triple Crown--One of those Myths is that Doping has tarnished the Triple Crown Series

John Scheinman, a former horse racing reporter for The Washington Post, is a freelance writer and editor. He contributes to the Blood-Horse, Thoroughbred Racing Commentary, Bleacher Report and other publications.  In the Washington Post Scheinman address his thoughts on whether doping has tarnished the Triple Crown and states:
 
3. Doping has tarnished the Triple Crown series.
The racing world at times has been awash in scandal and derision over medication and doping issues.
Yet elaborate security protocols were developed by state racing commissions for horses running in the Triple Crown following the death of the filly Eight Belles in the 2008 Kentucky Derby.
These days, the Triple Crown horses practically live in maximum-security prisons. State racing commission security at their stalls runs around the clock. Multiple blood samples are taken in the days leading up to the races and are examined in specialized labs. Vet records are monitored. Commission investigators or vets oversee the administration of all medications. Vials and syringes are taken by the commissions for possible testing. Entry and exit logs are kept to follow who goes in and out of the barns. Security cameras are in place. Post-race testing is also conducted. If anyone is cheating under such heavy scrutiny, they’re doing a damn good job of it.

quoted from here

Iowa Board of Pharmacy 2014 Annual Meeting scheduled for June 13-14

2014 Annual Meeting
5/27/2014

The 2014 Annual Meeting will be
The 2014 Annual Meeting will be held June 13-14 at Prairie Meadows Conference Center in Altoona.